[1]周竟心,姚金融,高 玲,等.血清白蛋白水平与弥漫性大B细胞淋巴瘤预后的相关性研究[J].医学信息,2023,36(18):78-83.[doi:10.3969/j.issn.1006-1959.2023.18.014]
　ZHOU Jing-Xin,YAO Jin-rong,GAO Ling,et al.Correlation Between Serum Albumin Level and Prognosis of Diffuse Large B-cell Lymphoma[J].Journal of Medical Information,2023,36(18):78-83.[doi:10.3969/j.issn.1006-1959.2023.18.014]
点击复制

血清白蛋白水平与弥漫性大B细胞淋巴瘤预后的相关性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年18期
页码:
78-83
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Correlation Between Serum Albumin Level and Prognosis of Diffuse Large B-cell Lymphoma
文章编号:
1006-1959（2023）18-0078-06
作者:
周竟心; 姚金融; 高 玲; 等
（1.南京医科大学附属宿迁市第一人民医院血液内科，江苏 宿迁 223800；2.徐州医科大学附属医院血液内科，江苏 徐州 221002）
Author(s):
ZHOU Jing-Xin; YAO Jin-rong; GAO Ling; et al.
(1.Department of Hematology,Suqian First People’s Hospital Affiliated to Nanjing Medical University,Suqian 223800,Jiangsu,China;2.Department of Hematology,the Affiliated Hospital of Xuzhou Medical University,Xuzhou 221002,Jiangsu,China)
关键词:
弥漫性大B细胞淋巴瘤; 血清白蛋白; 生存时间
Keywords:
Diffuse large B-cell lymphoma; Serum albumin; Survival time
分类号:
R733
DOI:
10.3969/j.issn.1006-1959.2023.18.014
文献标志码:
A
摘要:
目的 探讨血清白蛋白水平与弥漫性大B细胞淋巴瘤（DLBCL）危险度分层和预后的相关性。方法 选择2018年1月-2019年1月宿迁市第一人民医院血液内科收治的32例DLBCL患者作为观察组，另外选取来自本院体检中心的32名年龄、性别相匹配的健康人作为对照组，收集两组临床资料及血液标本，比较两组白蛋白（ALB）、白细胞计数（WBC）、血红蛋白计数（HB）、血小板计数（PLT）。将观察组患者根据Ann Arbor分期、国际预后指数（IPI）分为Ⅲ+Ⅳ组、Ⅰ+Ⅱ组，IPI（2~5）组、IPI（0~1）组，分别比较各亚组之间HB、ALB、乳酸脱氢酶、IL-6、IL-10水平。在治疗前按照白蛋白水平的不同把患者分为ALB＞33.5 g/L，ALB≤33.5 g/L组，比较两组Ann Arbor分期、IPI，采用回归模型确定DLBCL的危险因素。结果 观察组血清ALB、WBC、HB、PLT均低于对照组（P＜0.05）；Ⅲ+Ⅳ组治疗前HB、ALB水平低于Ⅰ+Ⅱ组，乳酸脱氢酶水平高于Ⅰ+Ⅱ组（P＜0.05）；IPI（2~5）组IL-6、IL-10、乳酸脱氢酶水平高于IPI（0~1）组，ALB、HB、PLT低于IPI（0~1）组（P＜0.05）；与ALB＞33.5 g/L组比较，ALB≤33.5 g/L组Ann Arbor分期晚、IPI高、生存时间短（P＜0.05）；二元Logistic回归模型分析显示，ALB是DLBCL的独立危险因素（P＜0.05）；COX风险模型回归分析显示，乳酸脱氢酶升高、ALB≤33.5 g/L是影响患者预后的独立因素（P＜0.05）。结论 ALB≤33.5 g/L是影响DLBCL患者预后的因素，在评估 DLBCL患者预后中有一定的指导价值。
Abstract:
Objective To investigate the relationship between serum albumin level and risk stratification, prognosis of diffuse large B-cell lymphoma (DLBCL).Methods Thirty-two patients with DLBCL admitted to the Department of Hematology, Suqian First People’s Hospital from January 2018 to January 2019 were selected as the observation group. In addition, 32 healthy people with matching age and gender from the physical examination center of our hospital were selected as the control group. The clinical data and blood samples of the two groups were collected, and the albumin (ALB), white blood cell count (WBC), hemoglobin count (HB) and platelet count (PLT) were compared between the two groups. The patients in the observation group were divided into Ⅲ+Ⅳ group, Ⅰ+Ⅱ group, IPI (2-5) group and IPI (0-1) group according to Ann Arbor stage and international prognostic index (IPI), the levels of HB, ALB, lactate dehydrogenase, IL-6 and IL-10 were compared among the subgroups. Before treatment, the patients were divided into ALB>33.5 g/L group and ALB≤33.5 g/L group according to different albumin levels. The Ann Arbor stage and IPI were compared between the two groups, and the risk factors of DLBCL were determined by regression model.Results The levels of serum ALB, WBC, HB and PLT in the observation group were lower than those in the control group (P<0.05). Before treatment, the levels of HB and ALB in Ⅲ+Ⅳ group were lower than those in Ⅰ+Ⅱ group, and the level of lactate dehydrogenase was higher than that in Ⅰ+Ⅱ group (P<0.05). The levels of IL-6, IL-10 and lactate dehydrogenase in IPI (2-5) group were higher than those in IPI (0-1) group, and the levels of ALB, HB and PLT were lower than those in IPI (0-1) group (P<0.05). Compared with ALB>33.5 g/L group, ALB≤33.5 g/L group had late Ann Arbor stage, high IPI and short survival time (P<0.05). Binary Logistic regression model analysis showed that ALB was an independent risk factor for DLBCL (P<0.05). COX risk model regression analysis showed that elevated lactate dehydrogenase and ALB≤33.5 g/L were independent factors affecting the prognosis of patients (P<0.05).Conclusion ALB≤33.5 g/L is a factor affecting the prognosis of DLBCL patients, and it has certain guiding value in evaluating the prognosis of DLBCL patients.

参考文献/References:

[1]Lang R,Gill MJ.Diffuse Large B-Cell Lymphoma[J].N Engl J Med,2021,384(23):2261-2262. [2]Ennishi D,Hsi ED,Steidl C,et al.Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma[J].Cancer Discov,2020,10(9):1267-1281.[3]Takyar J,Raut M,Borse R,et al.Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices[J].Expert Rev Hematol,2020,13(3):275-287.[4]Harris LJ,Patel K,Martin M.Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J].Int J Mol Sci,2020,21(22):8553. [5]Wight JC,Chong G,Grigg AP,et al.Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI[J].Blood Rev,2018,32(5):400-415. [6]Long L,Tan X,Liu Z,et al.Effects of Human Serum Albumin on the Fluorescence Intensity and Tumor Imaging Properties of IR-780 Dye[J].Photochem Photobiol,2022,98(4):935-944.[7]Yang Z,Zheng Y,Wu Z,et al.Association between pre-diagnostic serum albumin and cancer risk: Results from a prospective population-based study[J].Cancer Med,2021,10(12):4054-4065.[8]Tao HY,Wang RQ,Sheng WJ,et al.The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy[J].Int J Biol Macromol,2021,187:24-34. [9]Zeeshan F,Madheswaran T,Panneerselvam J,et al.Kesharwani P. Human Serum Albumin as Multifunctional Nanocarrier for Cancer Therapy[J].J Pharm Sci,2021,110(9):3111-3117. [10]中华医学会血液学分会.中国弥漫大B细胞淋巴瘤诊断与治疗指南[J].中华血液学杂志,2013,34(9):816-819.[11]He J,Chen Z,Xue Q,et al.Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature[J].J Transl Med,2022,20(1):186.[12]Go SI,Park S,Kim JH,et al.A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma[J].Tumori,2018,104(4):292-299. [13]Ozturk E,Elibol T,Kilicaslan E,et al.Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma[J].Medeni Med J,2022,37(1):85-91. [14]Vannata B,Conconi A,Winkler J,et al.Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome[J].Br J Haematol,2019,187(4):478-487.[15]Ruppert AS,Dixon JG,Salles G,et al.International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI[J].Blood,2020,135(23):2041-2048. [16]Litus EA,Permyakov SE,Uversky VN,et al.Intrinsically disordered regions in serum albumin: what are they for?[J].Cell Biochem Biophys,2018,76(1-2):39-57. [17]Islam MS,Islam MN,Kundu SK,et al.Serum albumin level and in-hospital outcome of patients with first attack acute myocardial infarction[J].Mymensingh Med J,2019,28(4):744-751.[18]Ouyang X,Dang Y,Zhang F,et al.Low serum albumin correlates with poor survival in Gastric Cancer Patients[J].Clin Lab,2018,64(3):239-245.[19]Kaymak Cerkesli ZA,Ozkan EE,Ozseven A.The esophageal dose-volume parameters for predicting Grade I-II acute esophagitis correlated with weight loss and serum albumin decrease in lung cancer radiotherapy[J].J Cancer Res Ther,2021,17(1):94-98. [20]Friedl M,Stoiber S,Brkic FF,et al.Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma[J].Biomedicines,2022,10(1):191. [21]Hohloch K,Ziepert M,Truemper L,et al.Low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma: Results from prospective trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group[J].EJHaem,2020,1(1):181-187. [22]Chiu E,Samra B,Tam E,et al.Clinical Characteristics and Outcomes of Caribbean Patients With Adult T-Cell Lymphoma/Leukemia at Two Affiliated New York City Hospitals[J].JCO Glob Oncol,2020,6:548-556. [23]Zhang L,Fang Y,Li L,et al.Human serum albumin-based drug-free macromolecular therapeutics: apoptosis induction by coiled-coil-mediated cross-linking of CD20 antigens on lymphoma B cell surface[J].Macromol Biosci,2018,18(11):e1800224.[24]Freedman A,Jacobsen E.Follicular lymphoma: 2020 update on diagnosis and management[J].Am J Hematol,2020,95(3):316-327.

相似文献/References:

[1]聂今心,丁振江,段华莹.心力衰竭患者血清脑钠肽和白蛋白相关性分析[J].医学信息,2019,32(05):98.[doi:10.3969/j.issn.1006-1959.2019.05.029]
　NIE Jin-xin,DING Zhen-jiang,DUAN Hua-ying.Correlation between Serum Brain Natriuretic Peptide and Albumin in Patients with Heart Failure[J].Journal of Medical Information,2019,32(18):98.[doi:10.3969/j.issn.1006-1959.2019.05.029]
[2]陈云娥,李 璠,张子怡,等.营养支持治疗对终末期恶性肿瘤患者临床结局影响的Meta分析[J].医学信息,2019,32(19):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
　CHEN Yun-e,LI Fan,ZHANG Zi-yi,et al.Meta-analysis of Effect of Nutritional Support Therapy on Clinical Outcome of Patients with Terminal-stage Malignant Tumor[J].Journal of Medical Information,2019,32(18):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
[3]马国瑞,马 燕.腹腔镜在早期胃癌治疗中的应用效果[J].医学信息,2021,34(09):125.[doi:10.3969/j.issn.1006-1959.2021.09.033]
　MA Guo-rui,MA Yan.Application Effect of Laparoscopy in the Treatment of Early Gastric Cancer[J].Journal of Medical Information,2021,34(18):125.[doi:10.3969/j.issn.1006-1959.2021.09.033]
[4]祖克拉·吐尔洪,印婷婷,努尔孜叶·阿布里克木.血清白蛋白水平对慢性心力衰竭心脏再同步化治疗患者预后的预测价值[J].医学信息,2021,34(15):89.[doi:10.3969/j.issn.1006-1959.2021.15.023]
　Zukra·Turhong,YIN Ting-ting,Nurziye·Abrikmu.Predictive Value of Serum Albumin Level in the Prognosis of Patients with Chronic Heart Failure and Cardiac Resynchronization Therapy[J].Journal of Medical Information,2021,34(18):89.[doi:10.3969/j.issn.1006-1959.2021.15.023]

更新日期/Last Update: 1900-01-01